BACKGROUND: VEGF (Vascular Endothelial Growth Factor) is a key factor of angiogenesis and high tissue VEGF levels are related to a poor prognosis in breast cancer. MATERIALS AND METHODS: By semi-quantitative RT-PCR, we determined the relative expressions of VEGF mRNA in MCF-7 (both ER-alpha+ and ER-beta+ (mainly ER-alpha+), PR+, bcl-2+, EGFR-) and MB-MDA-231 (only ER-beta+, PR-, EGFR-) breast cancer cells which were treated with estrogen, tamoxifen and EGF (Epidermal Growth Factor). RESULTS: In MCF-7 cell lines, estrogen induced the expression of VEGF mRNA while tamoxifen reduced its expression. Estrogen and tamoxifen did not confer any significant effect on MB-MDA-231 cells and EGF showed no significant effect on MCF-7 or MB-MDA-231. CONCLUSION: Reduced VEGF mRNA expression of MCF-7 cells treated with tamoxifen may be related to the antagonistic effect of tamoxifen on ER-positive breast cancer, and this antagonistic effect may be related to ER-alpha.
BACKGROUND:VEGF (Vascular Endothelial Growth Factor) is a key factor of angiogenesis and high tissue VEGF levels are related to a poor prognosis in breast cancer. MATERIALS AND METHODS: By semi-quantitative RT-PCR, we determined the relative expressions of VEGF mRNA in MCF-7 (both ER-alpha+ and ER-beta+ (mainly ER-alpha+), PR+, bcl-2+, EGFR-) and MB-MDA-231 (only ER-beta+, PR-, EGFR-) breast cancer cells which were treated with estrogen, tamoxifen and EGF (Epidermal Growth Factor). RESULTS: In MCF-7 cell lines, estrogen induced the expression of VEGF mRNA while tamoxifen reduced its expression. Estrogen and tamoxifen did not confer any significant effect on MB-MDA-231 cells and EGF showed no significant effect on MCF-7 or MB-MDA-231. CONCLUSION: Reduced VEGF mRNA expression of MCF-7 cells treated with tamoxifen may be related to the antagonistic effect of tamoxifen on ER-positive breast cancer, and this antagonistic effect may be related to ER-alpha.
Authors: Jacqueline A Nichols; Maria Chiara Perego; Luis F Schütz; Amber M Hemple; Leon J Spicer Journal: J Anim Sci Date: 2019-07-02 Impact factor: 3.159
Authors: Thomas W Bonagura; Jeffery S Babischkin; Graham W Aberdeen; Gerald J Pepe; Eugene D Albrecht Journal: Endocrinology Date: 2012-04-11 Impact factor: 4.736
Authors: Jeffery S Babischkin; Graham W Aberdeen; Jonathan R Lindner; Thomas W Bonagura; Gerald J Pepe; Eugene D Albrecht Journal: Endocrinology Date: 2019-06-01 Impact factor: 4.736
Authors: Katherine W Reeves; Roberta B Ness; Roslyn A Stone; Joel L Weissfeld; Victor G Vogel; Robert W Powers; Francesmary Modugno; Jane A Cauley Journal: Cancer Causes Control Date: 2008-11-06 Impact factor: 2.506